Optimization of dosing regiments of sulindac in combination with erlotinib for small intestinal and colon cancer prevention
Ended Awarded Last action
- Contract number
- 75N91019F00130
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $854,290
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Contract value 100% obligated
- $854,290.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The University of Texas M.D. Anderson Cancer Center has been awarded a $854,290 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ vehicle held by the National Cancer Institute. Under this contract, M.D. Anderson will conduct optimization of dosing regimens of sulindac in combination with erlotinib for small intestinal and colon cancer prevention. The work directly supports the National Cancer Institute's PREVENT preclinical drug development program and its goal of preclinical efficacy testing and intermediate biomarker identification. Funding is provided by the Department of Health and Human Services National Institutes of Health National Cancer Institute. Performance will occur in Houston, Texas over a three year period concluding in January 2022.
Quick answers
Who was awarded contract 75N91019F00130?
75N91019F00130 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on July 8, 2019.
How much is contract 75N91019F00130 worth?
The government has obligated $854,290 on 75N91019F00130.
Is contract 75N91019F00130 an order under another contract?
Yes. 75N91019F00130 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00130 competed?
The extent of competition for 75N91019F00130 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award